A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
Small bowel adenocarcinoma (SBA) is rare. For unresectable or recurrent SBA, systemic treatment is the only potentially promising option.



This retrospective study included 13 patients with SBA treated at our Institute. All patients received fluorouracil- or fluoropyrimidine-based regimens. We analyzed associations between the progression-free interval (PFI) and therapeutic regimen (n=17) and patient characteristics.



The 5-year overall survival of patients with SBA was 23.5%. The 5-year relapse-free survival of patients with curatively resected (R0 or R1) SBA (n=6) was 45%. Patients with unresectable or recurrent SBA (n=10) had a median overall survival time of 28.0 months. No factor was significantly associated with PFI, except the number of treatment regimens required: patients that received only one line of treatment survived significantly longer than those receiving multiple lines.



Fluorouracil- or fluoropyrimidine-based regimens might effectively treat unresectable or recurrent SBA. We did not investigate any additive agents that might have increased efficacy of these regimens.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Shunichiro
S
Makino
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan htakahashi@gesurg.med.osaka-u.ac.jp.
Hidekazu
H
Takahashi
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Naotsugu
N
Haraguchi
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Junichi
J
Nishimura
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Taishi
T
Hata
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Chu
C
Matsuda
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Masakazu
M
Ikenaga
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Kohei
K
Murata
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Hirofumi
H
Yamamoto
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Yuichiro
Y
Doki
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Masaki
M
Mori
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Tsunekazu
T
Mizushima
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D007421:Intestine, Small / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D011743:Pyrimidines; D005472:Fluorouracil
Unresectable; chemotherapy; recurrent; small bowel adenocarcinoma